Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2019 07:00 ET | Source: ExCellThera

ExCellThera announces publication in The Lancet Haematology highlighting excellent clinical results of ECT-001 in patients with haematological malignancies

MONTREAL, Nov. 06, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use,...
May 07, 2019 08:05 ET | Source: ExCellThera

ExCellThera enters into a manufacturing and collaboration agreement with New York Blood Center

MONTREAL, May 07, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
April 23, 2019 08:05 ET | Source: ExCellThera

ExCellThera’s lead technology, ECT-001, receives FDA Regenerative Medicine Advanced Therapy (RMAT) designation

MONTREAL, April 23, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
March 25, 2019 08:07 ET | Source: ExCellThera

ExCellThera announces clearance by FDA and Health Canada for ECT-001 in new clinical trials in United States and Canada for the treatment of leukemia

MONTREAL, March 25, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for...
December 17, 2018 08:05 ET | Source: ExCellThera

ExCellThera receives FDA orphan drug designation for ECT-001 for the prevention of graft-versus-host disease

MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced...
December 04, 2018 07:05 ET | Source: ExCellThera

ExCellThera announces results of clinical trial using ECT-001 for blood cancers

MONTREAL, Dec. 04, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
November 08, 2018 07:05 ET | Source: ExCellThera

ExCellThera announces clinical trial results using ECT-001 to be presented at ASH 2018 annual meeting

MONTREAL, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today...
June 27, 2018 08:50 ET | Source: ExCellThera

Final patient receives treatment in stem cell clinical trial for severe blood cancers

MONTREAL, June 27, 2018 (GLOBE NEWSWIRE) -- ExCellThera Inc., a biotechnology company delivering molecules and bioengineering solutions to expand blood stem cells for therapeutic use, announced...

keyboard_arrow_left Previous Page